JAKARTA, Indonesia, Nov. 17, 2022 /PRNewswire/ — Asa Ren Pte Ltd (“Asa Ren“), a leading consumer DNA data company based in Indonesia, has announced a strategic partnership with leading UAE-based Artificial Intelligence technology company, G42 Health Care AI Holding RSC LTD (“G42 Healthcare”). This collaboration is intended to develop and enhance the genomic sequencing and bioinformatics capability in Indonesia in preparation for the Biomedical Genome Science Initiatives (“BGSi”), with the use of microarray methods and whole genome sequencing in the context of laboratory activities.
Signing Ceremony Memorandum of Understanding between Asa Ren (Indonesia) and G42 Healthcare (United Arab Emirates) on 14 November 2022. From left to right: H.E Dr Thani bin Ahmed Al Zeyoudi (Minister of State for Foreign Trade UAE), Ashish Koshy (CEO of G42 Healthcare), Aloysius Liang (CEO of Asa Ren), Budi Gunawan Sadikin (Minister of Health the Republic of Indonesia), and Charles Honoris (Deputy Chairman of Healthcare Chamber of Commerce Indonesia).
The Indonesian genomic industry’s CAGR is projected to grow at a compound annual growth rate (CAGR) of 11.4% from 2020 to 2027, and this collaboration will allow both companies to be at the forefront of this once-in-a-lifetime opportunity.
The MoU between G42 Healthcare and Asa Ren is aimed at developing and enhancing genomic sequencing and bioinformatics capabilities in Indonesia to support National Genomics Initiatives in the country and delivering long-term value.
The signing ceremony of this agreement was conducted at UAE Business Forum in side-event of B20 Summit during the held of G20 Indonesia 2022 and was attended by the Coordinating Minister of Maritime and Investment Affairs of Indonesia, Luhut Binsar Pandjaitan; UAE Ambassador for Indonesia, H.E. Abdullah Salem Al Dhaheri, Minister of Health the Republic of Indonesia, Budi Gunawan Sadikin; Minister of State for Foreign Trade, H.E Dr Thani bin Ahmed Al Zeyoudi; and Deputy Chairman of Healthcare Chamber of Commerce Indonesia, Charles Honoris.
Announcing the partnership, Aloysius Liang, CEO of Asa Ren said: “Together, this partnership will drive a transformation in Indonesia’s genomic industry and elevate the entire healthcare and biotech ecosystem to deliver long-term value with both G42 Healthcare and Asa Ren’s combined technologies and expertise.”
In his comments on the collaboration, Ashish Koshy, CEO of G42 Healthcare said: “G42 Healthcare is committed to pushing the boundaries of innovation with world leaders in the healthcare sector. We have collaborated with global companies to offer impactful solutions across the healthcare value chain. Our partnership with Asa Ren will enable support of the national genomics initiatives and realize the shared vision of delivering comprehensive genome data, biological insights, and healthcare outcomes for personalized and preventive healthcare delivery in Indonesia.”
The two entities aim to also work together on joint proposals to government entities to develop and expand the electronic health passport, telehealth, and health data analysis. The MoU is also expected to build a genome biobank that can accelerate personalized healthcare experience for the community.
Rapid advancements in each step of Next-Gene Sequencing Analytical pipeline from Primary to Tertiary Analysis will enable both companies to drive the mission of building the largest Asian biobank and further enhance the application of the resulting analytical capability of the partnership.
About Asa Ren
Asa Ren is the leading South East Asia consumer DNA data company. We provide an end-to-end DNA genotyping platform -from wet lab services to bioinformatics- for leading hospital groups, clinics and healthcare companies.
With a comprehensive user experience and adaptive business model, Asa Ren’s suite of technology allows our customers to understand and manage their own healthcare data through genetic profile, 360 phenotype, and users’ medical profile, Asa Ren aims to build a longitudinal dataset for a more personalized healthcare experience.
The importance of building health profiles, developing the data infrastructure and providing extensive population health focused analytics is significant. Asa Ren aims to be an integral part within the big health data sector and collaborate with strategic partners that have an aligned vision in bringing higher quality and more personalized healthcare. Asa Ren’s vision is to build the largest global biobank.
For more information about us, visit here https://asaren.ai/
About G42 Healthcare
G42 Healthcare, a leading health-tech company, is on a mission to develop a world-class healthcare sector in the UAE and beyond, by harnessing data and advanced medical technologies to unlock the potential of personalized and preventive care and transforming the traditional healthcare ecosystem. We have built Biogenex Labs, UAE’s first COVID-19 accredited large-scale throughput laboratory, facilitated the 4Humanity clinical trials, the world’s first phase three trial for inactivated vaccine against COVID-19 with over 43,000 volunteers from 125+ nationalities across the pan-Arab region, established the region’s first dedicated contract research organization (IROS) for conducting clinical research with and for local populations, supported UAE’s healthcare authorities on the national vaccination implementation, conducted research into new vaccines and drug therapies, and built Omics Centre of Excellence, the region’s largest and most technologically advanced Omics facility that is the backbone for the Emirati Genome Program, the world’s most comprehensive population genomics initiative.
For further information on G42 Healthcare, visit https://www.g42healthcare.ai
Adhetya Ghazitha Kasim – Corporate Development
Asa Ren Pte Ltd
Email: [email protected]
Discussion about this post